634 related articles for article (PubMed ID: 20050847)
1. On setting the first dose in man: quantitating biotherapeutic drug-target binding through pharmacokinetic and pharmacodynamic models.
Lowe PJ; Tannenbaum S; Wu K; Lloyd P; Sims J
Basic Clin Pharmacol Toxicol; 2010 Mar; 106(3):195-209. PubMed ID: 20050847
[TBL] [Abstract][Full Text] [Related]
2. The minimum anticipated biological effect level (MABEL) for selection of first human dose in clinical trials with monoclonal antibodies.
Muller PY; Milton M; Lloyd P; Sims J; Brennan FR
Curr Opin Biotechnol; 2009 Dec; 20(6):722-9. PubMed ID: 19896825
[TBL] [Abstract][Full Text] [Related]
3. Quantitative pharmacology or pharmacokinetic pharmacodynamic integration should be a vital component in integrative pharmacology.
Gabrielsson J; Green AR
J Pharmacol Exp Ther; 2009 Dec; 331(3):767-74. PubMed ID: 19779129
[TBL] [Abstract][Full Text] [Related]
4. Clinical pharmacokinetics: current requirements and future perspectives from a regulatory point of view.
Shah RR
Xenobiotica; 1993 Nov; 23(11):1159-93. PubMed ID: 8310705
[TBL] [Abstract][Full Text] [Related]
5. Anticancer Drug Development: The Way Forward.
Connors T
Oncologist; 1996; 1(3):180-181. PubMed ID: 10387985
[TBL] [Abstract][Full Text] [Related]
6. Safety evaluation to support First-In-Man investigations I: kinetic and safety pharmacology studies.
Baldrick P
Regul Toxicol Pharmacol; 2008 Jul; 51(2):230-6. PubMed ID: 18501489
[TBL] [Abstract][Full Text] [Related]
7. [Clinical-pharmacological aspects to accelerate the development process from the preclinical to the clinical phase/1st communication: The contribution of clinical pharmacology].
Kuhlmann J
Arzneimittelforschung; 2004; 54(5):251-8. PubMed ID: 15212186
[TBL] [Abstract][Full Text] [Related]
8. Drug research: from the idea to the product.
Kuhlmann J
Int J Clin Pharmacol Ther; 1997 Dec; 35(12):541-52. PubMed ID: 9455711
[TBL] [Abstract][Full Text] [Related]
9. Keynote review: in vitro safety pharmacology profiling: an essential tool for successful drug development.
Whitebread S; Hamon J; Bojanic D; Urban L
Drug Discov Today; 2005 Nov; 10(21):1421-33. PubMed ID: 16243262
[TBL] [Abstract][Full Text] [Related]
10. Safety assessment and dose selection for first-in-human clinical trials with immunomodulatory monoclonal antibodies.
Muller PY; Brennan FR
Clin Pharmacol Ther; 2009 Mar; 85(3):247-58. PubMed ID: 19177065
[TBL] [Abstract][Full Text] [Related]
11. Alternative strategies in drug development: clinical pharmacological aspects.
Kuhlmann J
Int J Clin Pharmacol Ther; 1999 Dec; 37(12):575-83. PubMed ID: 10599949
[TBL] [Abstract][Full Text] [Related]
12. [Responsibilities of clinical pharmacology in the early phase of drug development].
Kuhlmann J
Med Klin (Munich); 2000 May; 95(1 Spec No):31-40. PubMed ID: 10851846
[TBL] [Abstract][Full Text] [Related]
13. Analysis of pharmacology data and the prediction of adverse drug reactions and off-target effects from chemical structure.
Bender A; Scheiber J; Glick M; Davies JW; Azzaoui K; Hamon J; Urban L; Whitebread S; Jenkins JL
ChemMedChem; 2007 Jun; 2(6):861-73. PubMed ID: 17477341
[TBL] [Abstract][Full Text] [Related]
14. The application of target information and preclinical pharmacokinetic/pharmacodynamic modeling in predicting clinical doses of a Dickkopf-1 antibody for osteoporosis.
Betts AM; Clark TH; Yang J; Treadway JL; Li M; Giovanelli MA; Abdiche Y; Stone DM; Paralkar VM
J Pharmacol Exp Ther; 2010 Apr; 333(1):2-13. PubMed ID: 20089807
[TBL] [Abstract][Full Text] [Related]
15. Safety evaluation to support First-In-Man investigations II: toxicology studies.
Baldrick P
Regul Toxicol Pharmacol; 2008 Jul; 51(2):237-43. PubMed ID: 18501490
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic and pharmacodynamic modeling in vivo.
Holford NH; Sheiner LB
Crit Rev Bioeng; 1981; 5(4):273-322. PubMed ID: 7023829
[TBL] [Abstract][Full Text] [Related]
17. [Role of pharmacokinetic-pharmacodynamic relationships in drug development].
Bellissant E; Courcier-Duplantier S; Blin O;
Therapie; 2002; 57(4):347-57. PubMed ID: 12422555
[TBL] [Abstract][Full Text] [Related]
18. Early integration of pharmacokinetic and dynamic reasoning is essential for optimal development of lead compounds: strategic considerations.
Gabrielsson J; Dolgos H; Gillberg PG; Bredberg U; Benthem B; Duker G
Drug Discov Today; 2009 Apr; 14(7-8):358-72. PubMed ID: 19162219
[TBL] [Abstract][Full Text] [Related]
19. Basic principles and techniques of pharmacokinetic modeling.
Riviere JE
J Zoo Wildl Med; 1997 Mar; 28(1):3-19. PubMed ID: 9226611
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of an integrated in vitro-in silico PBPK (physiologically based pharmacokinetic) model to provide estimates of human bioavailability.
Cai H; Stoner C; Reddy A; Freiwald S; Smith D; Winters R; Stankovic C; Surendran N
Int J Pharm; 2006 Feb; 308(1-2):133-9. PubMed ID: 16352407
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]